Godavari Biorefineries Limited has achieved a major milestone in its global innovation journey, with the validation of its European patent for a breakthrough anti-cancer molecule. The patent has now been officially recognized in Spain, the United Kingdom, and as a Unitary Patent covering several key European Union member states.
This development marks a significant leap forward for Godavari Biorefineries’ efforts in high-impact healthcare innovation, particularly through its Anti-Cancer Research Segment.
The patented molecule has demonstrated strong efficacy in targeting both cancer cells and cancer stem cells, indicating its potential as a next-generation treatment for difficult-to-treat cancers, including breast and prostate cancers. Early-stage preclinical studies have shown encouraging results in terms of both effectiveness and safety. The molecule is currently undergoing Phase 1a clinical trials to evaluate its safety in patients with advanced solid tumors, as well as in healthy volunteers.
Speaking on the achievement, Sangeeta Srivastava, Executive Director of Godavari Biorefineries, said, “This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research. It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation.”
The company’s biotech subsidiary, Sathgen Therapeutics, is spearheading the development of this anti-cancer molecule. Sathgen is known for its work on novel cancer and antiviral therapies and represents Godavari Biorefineries’ growing focus on translational research aimed at solving some of the world’s most critical health challenges.
Already exporting to over 20 countries, Godavari Biorefineries is globally recognized for its leadership in ethanol, bio-based chemicals, and renewable materials. The foray into clinical-stage biotech further underlines the company’s commitment to scientific diversification and global healthcare impact.
